Infographic: Ibogaine, the Psychedelic Underdog

Of all the psychedelic substances around the world, it’s likely that ibogaine isn’t the first, second, or third to come to mind. In fact, ibogaine (Tabernanthe iboga) known as an “atypical psychedelic.” This classification separates it from classic or classical psychedelics like LSD, psilocybin, and ayahuasca based on which neuro-receptors it affects.

Although, not a popstar, ibogaine has seen various uses over the last century (and beyond) and shows amazing potential that hasn’t been fully realized. Those uses range from treating depression and fatigue to blowing other addiction treatments out of the water.

So, if ibogaine can treat addiction like nothing else can, why aren’t there treatment centers all over the world?

‍Especially in the midst of an opioid epidemic?

Well, like any medicine, ibogaine needs to undergo a series of testing in the form of pre-clinical and clinical trials before it can be used to help people. While ibogaine treatment is available in several locations outside of Canada and the US, access isn’t practical for most people who need it. Worth noting is that ibogaine was until not long ago (2017!) unregulated and so, legal, in Canada. As the story goes, treatment centers closed abruptly after a patient forged an EKG and was harmed.

Ibogaine has immense power, a trait that also assumes a focus on responsibility. In short, ibogaine has been determined to accelerate certain heart conditions due to a level of cardiotoxicity that has yet to be understood.

That’s where MINDCURE comes in. We’re synthesizing a consistent and reliable source of ibogaine to supply both our research team and other researchers as they conduct pre-clinical explorations.

These trials will help uncover potential uses for ibogaine in clinical settings, develop protocols, and measure dosage and safety measures.

We can’t wait to learn more about ibogaine, and we bet you can’t either. That’s why we’ve put together the following infographic to share some knowledge about this incredible compound.

Sources:

1. Langlois JA, Rutland-Brown W, Wald MM. The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil. 2006;21(5):375-378. doi:10.1097/00001199-200609000-00001
2. Weatherall MW. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015;6(3):115-123. doi:10.1177/2040622315579627
3. Remes O, Brayne C, van der Linde R, Lafortune L. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav. 2016;6(7):e00497. Published 2016 Jun 5. doi:10.1002/brb3.497
4. Belzak, L., & Halverson, J. (2018). The opioid crisis in Canada: a national perspective. Health promotion and chronic disease prevention in Canada: research, policy and practice, 38(6), 224–233. https://doi.org/10.24095/hpcdp.38.6.02
5. LaRosa J. $38 billion U.S. addiction rehab industry pivots to cope during covid-19 pandemic. Market Research. https://blog.marketresearch.com/38-billion-u.s.-addiction-rehab-industry-pivots-to-cope-during-covid-19-pandemic. Published July 27, 2020. Accessed December 7, 2021.